superficial lipoma. Benign lipomatous neoplasm
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: having at least one lipoma (clinically and sonographically proven) and accessible for diagnostic and therapeutic approaches with at least two vertical axes measurable and with the following conditions:The history of gradual growth, stability in the last 6 months, single and isolated, with an oval to circular shape, without a hard consistency or connection to the underlying tissue, in the areas of the limbs and trunk and away from sensitive vascular-neural structures Weight stability and body mass index less than 30 in the last 3 months Ability to complete the study and follow instructions Informed consent to participate in the study Consent not to undergo any other intervention for lipoma during the study period
Exclusion criteria
Exclusion criteria: Severe medical or psychological conditions that interfere with study results History of hypersensitivity to any of the components of the studied product Pregnancy and breastfeeding History of previous lipoma treatment BMI >?? Patients prone to intravascular volume depletion Evidence of recent alcohol consumption or drug abuse History of bleeding disorders or recent intake (less than 3 weeks) of thrombolytic drugs, anticoagulants, platelet inhibitors, or NSAIDs History of hypertrophic scarring Infection, inflammation, dermatosis, non-healing wound, cancer or precancerous lesions at the lipoma site
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipoma size reduction percentage. Timepoint: At the beginning of the study, before each injection session monthly up to 3 times, one month after the last injection. Method of measurement: Ultrasound. | — |
Countries
Iran (Islamic Republic of)
Contacts
Tehran University of Medical Sciences